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ABSTRACT: Structure-based computational peptide design
methods have gained signiﬁcant interest in recent years owing
to the availability of structural insights into protein−protein
interactions obtained from the crystal structures. The majority
of these approaches design new peptide ligands by connecting
the crucial amino acid residues from the protein interface and
are generally not based on any predicted receptor−ligand
interaction. In this work, a peptide design method based on
the Knob−Socket model was used to identify the speciﬁc
ligand residues packed into the receptor interface. This
method enables peptide ligands to be designed rationally by
predicting amino acid residues that will ﬁt best at the binding
site of the receptor protein. In this, speciﬁc peptide ligands
were designed for the model receptor CD13, overexpression of which has been observed in several cancer types. From the initial
library of designed peptides, three potential candidates were selected based on simulated energies in the CD13 binding site
using the programs molecular operating environment and AutoDock Vina. In the CD13 enzymatic activity inhibition assay, the
three identiﬁed peptides exhibited 2.7−7.4 times lower IC50 values (GYPAY, 227 μM; GFPAY, 463 μM; GYPAVYLF, 170 μM)
as compared to the known peptide ligand CNGRC (C1−C5) (1260 μM). The apparent binding aﬃnities of the peptides
(GYPAY, Ki = 54.0 μM; GFPAY, Ki = 74.3 μM; GYPAVYLF, Ki = 38.8 μM) were 10−20 times higher than that of CNGRC
(C1−C5) (Ki = 773 μM). The double reciprocal plots from the steady-state enzyme kinetic assays conﬁrmed the binding of the
peptides to the intended active site of CD13. The cell binding and confocal microscopy assays showed that the designed
peptides selectively bind to the CD13 on the cell surface. Our study demonstrates the feasibility of a Knob−Socket-based
rational design of novel peptide ligands in improving the identiﬁcation of speciﬁc binding versus current more labor-intensive
methods.

■

INTRODUCTION
The world of medicine is moving fast toward precision and
personalized care where drugs are being tailored according to
individual variability and delivered speciﬁcally to the diseased
tissue.1 One of the most popular strategies to enhance the
therapeutic eﬃcacy while minimizing the systemic toxicities
has been the active drug targeting with the aid of specially
designed ligand moieties.2−4
Antibodies, peptides, and aptamers are some of the
commonly used targeting molecules. Among these, peptides
possess several attractive features such as high target speciﬁcity,
reduced likelihood of unintended immunogenic interactions,
and smaller size leading to better tissue penetration and
favorable pharmacokinetic properties.5,6 There are more than
60 peptide drug products approved by US Food and Drug
Administration, with additional 140 peptide drugs in clinical
trials and more than 500 therapeutic peptides in preclinical
stage.7 Recent advancements in robust chemical synthesis and
© 2019 American Chemical Society

conjugation techniques are expected to further increase the use
of peptide-based molecules in diagnosis, imaging, and therapy.
The eﬃcient design of high-aﬃnity peptide ligands via
rational methods has been a major obstacle to the development
of this potential drug class.8 The most widely adopted strategy
to identify a new peptide ligand is phage display, where a large
library of peptides is screened against a predetermined
target.9−11 This high throughput technique has been a
powerful and versatile approach for peptide ligand identiﬁcation, but it is inherently time consuming and resource
demanding. One relatively new peptide design methodology,
the computational design method combines structural
information with docking, to develop new peptides.8 Campa
et al.12 reported the design of a novel type III epidermal
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(hCD13) is only available in a complex with the endogenous
ligand ANG IV (PDB ID: 4FYS).29 To conﬁrm the target site
for the peptide ligand, PDB ID: 4FYS and PDB ID: 4OU3
were loaded in molecular operating environment (MOE)
software (version 2013.08, Chemical Computing Group,
Montreal, QC, Canada) with a solution phase AMBER10:EHT
forceﬁeld and R-ﬁeld solvation model. Nonbinding portions of
the protein structures were then deleted keeping only the
binding site residues. For hCD13, the amino acids are A191−
A215, K340−L487, and R855−R908, and for pCD13, they are
A186−T210, K335−L482, and R852−R905. The homology
between the hCD13 and pCD13 binding sites was analyzed
using the Align and Superpose functions in the MOE.
Mapping the hCD13−ANG IV Binding Interface. The PDB
ﬁle of the hCD13−ANG IV complex (PDB ID: 4FYS) was
loaded in the University of California, San Francisco (UCSF)
Chimera program package.30 The program connected the
sequences of hCD13 and ANG IV together and renumbered all
the amino acids for the whole complex. (Dictionary of
secondary structure of proteins) program31 was used to assign
the secondary structure deﬁnition to the hCD13. An in-house
program named relative packing clique was used to precisely
deﬁne a set of all residues that contact each other and classify
them based on contact order.32 Contacts were calculated from
a Voronoi polyhedra analysis18 which included side-chain-toside-chain contacts and side-chain-to-main-chain contacts for
all the residues. In addition, contacts were considered for mainchain-to-main-chain contacts for all nonneighboring residues.
The resulting Delaunay tessellation deﬁnes a contact graph
between residues.19 On the basis of the calculated twodimensional contact graph, all sockets and knobs formed on
the binding interface were identiﬁed.
Designing Peptide Ligands. The sockets on the protein
that took part in ligand binding along with some other free
sockets were selected as the target site for the peptide ligands.
Peptides were then designed by selecting the amino acid
residues having highest (or second highest) propensities
toward the selected sockets on the target site (Table S1).33
When the distance between two knob residues was far because
of the physical separation between the two CD13 surface
sockets, ﬂanking amino acids were inserted to ﬁll the gap. A
database of ﬁve amino acid (5-mer) long peptides was created
using diﬀerent combinations of amino acids from the list of
highest (or second highest) propensity knobs. A second
database of eight amino acid (8-mer) long peptides was also
created using the same method to cover larger binding surface.
Screening of the Peptide Ligands. Peptide sequences were
ﬁrst screened from the initial database using the following
predetermined criteria. Peptides that have glutamine at the Nterminal can easily condense to form pyroglutamate degradation products.34 Peptides with Xaa-proline residues at the Nterminal may lead to diketopiperazine formation,35 and
oxidation of methionine produces sulfoxide amino acids.36
Consequently, peptides with glutamine or Xaa-proline on the
N-terminal or methionine in the sequence were discarded.
Additionally, peptides containing same amino acids consecutively were also removed from the initial database. The
remaining peptides were constructed in MOE using the
Molecule Builder tool, and energy minimization was
performed using the AMBER10:EHT forceﬁeld and R-ﬁeld
solvation model. After loading the hCD13−ANG IV complex
(PDB ID: 4FYS) in MOE, the protein structure was prepared
using the LigX function with the default setting except the

growth factor receptor (EGFRvIII) binding peptide through
hydropathic complementarity approach. Using the program
ANIMOMAT, the peptide sequences were designed to bind
EGFRvIII. In 2000, Park et al.13 published a study on the
design of a peptidomimetic having comparable biological
properties to those of an antibody. This peptidomimetic was
developed based on an analysis of the human epidermal
growth factor receptor 2 (HER2/neu)−antibody (anti-HER2/
neu) co-crystal structure. In another computer-assisted in silico
screening of a large virtual library of peptides by Song et al.,14
they selected a peptide ligand for EGFR binding. Generally,
peptides derived from an analysis of the protein interface
structure constitute the primary source of these designs.8
However, none of them identify peptide ligands using a model
that exactly deﬁnes the speciﬁc packing of the ligand residues
within a structure’s binding interface. Therefore, a rational
peptide design technique based on the clear mapping of amino
acid side-chain packing arrangements between ligand and
target proteins has distinct advantages. In this regard, the
Knob−Socket (KS) based approach could help to reduce the
development time by allowing rational and expeditious inprocess optimization and provides plausible alternatives to the
experimental high-resolution receptor protein−peptide complex structures.
In this study, a rational peptide design method is
investigated that clearly deﬁnes the packing of the ligand at
the binding site of the receptor protein. The method is based
on a novel description of protein-packing known as KS that
provides a simpliﬁed yet accurate representation of residue
packing between two molecules.15−17 The KS model uses the
precision of Voronoi polyhedra/Delaunay tessellations to
identify contacts18,19 and is described as a 4-residue tetrahedral
motif, where a one-residue knob belonging to a secondary
structure packs into a three-residue socket on another
secondary structure. The KS model also provides information
about the propensities of the knobs that most likely can pack
into a respective socket.
We employed this rational method to design peptide ligands
for a prototype target-tumor vascular endothelial cluster of
diﬀerentiation 13 (CD13) receptor. The CD13, also known as
aminopeptidase N, is a 967-residue type-2 cell surface
membrane glycoprotein. It is one of the tumor vasculature
biomarkers associated with several of the malignant phenotypes such as cell proliferation, secretion, invasion, and
angiogenesis. CD13 is overexpressed in many cancers such
as breast, kidney, prostate, ovarian, colon, gastric, pancreatic,
and thyroid cancer.20−25
CD13 is a good prototype target for the present study
because it has an established peptide ligand CNGRC (C1−
C5), identiﬁed through a phage display study, which can serve
as a direct comparison for the evaluation of designed peptides.
Additionally, this target allows a clean in vivo evaluation of the
designed peptides as the endothelial cells of the tumor
vasculature are readily accessible to the ligands, and the
vascular endothelial cells are genetically more stable than the
tumor cells in developing drug resistance.26,27

■

METHODS
Peptide Design. Conﬁrming the Peptide Binding Site on
Human CD13 (hCD13). The crystal structure of porcine CD13
(pCD13) is available in a complex with a peptide targeting
ligand CNGRCG (C1−C5) [protein data bank (PDB) ID:
4OU3].28 However, the crystal structure of human CD13
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group from the C-terminal lysine. Then FITC (AnaSpec,
Fremont, CA, USA) was coupled to the exposed primary
−NH2 group on the side chain of lysine.47 Finally, the FITClabeled peptides were cleaved from the resin using triﬂuoroacetic acid−water−triisopropylsilane (95:2.5:2.5) cocktail.
After synthesis, both unconjugated and FITC-conjugated
peptides were freeze-dried and puriﬁed using reversed phase
high-performance liquid chromatography (RP-HPLC). An
Agilent Zorbax C18, 5 μ, 4.6 × 150 mm (Agilent Technologies,
Santa Clara, CA, USA) column was used, and the eluents were
detected at 210, 254, and 280 nm. Water with 0.1%
triﬂuoroacetyl (TFA) (A) and acetonitrile with 0.1% TFA
(B) were used as mobile phase and eluted using a linear
gradient from 10 to 90% B over 30−35 min at 1.0 mL/min
ﬂow rate. After puriﬁcation, each product was found to have
more than 92% purity according as shown Table S2. Electronspray ionization mass spectrometry analysis conﬁrmed the
formation of each molecule (Table S2).
CD13 Catalysis Inhibition Assay. For the CD13 catalysis
inhibition assay,28,48−50 His-tagged human CD13 protein
(Sino Biological, Beijing, China) at 2 nM and 172 μM Lalanine 7-amido-4-methylcoumarin (Ala-MCA) (Santa Cruz
Biotechnology, Dallas, TX, USA) were incubated in 96-well
polystyrene microplates with 100 μL of binding buﬀer/well
[10 mM HEPES and 0.1% w/v bovine serum albumin (BSA)
in phosphate-buﬀered saline (PBS), pH 7.2] with gradient
concentrations of the peptides at 37 °C. The release of
ﬂuorescent product 7-amido-4-methylcoumarin was measured
using a BioTek Synergy HT microplate reader (BioTek
Instruments, Winooski, VT, USA) at λexc of 360 nm and λem
of 460 nm. The IC50 is deﬁned as the concentration of the
peptide causing 50% inhibition of the CD13 enzymatic activity.
The steady-state enzyme kinetic assays were performed at
room temperature as described above, using incremental
concentrations of Ala-MCA (33−526 μM), at ﬁxed concentrations of the peptides ranging from 0 to 1304 μM. Initial
rates (V0) were calculated from the slopes of the ﬁrst 5 min of
the reaction. The inhibitory constants (Ki) were calculated
using either competitive or noncompetitive enzyme inhibition
model in GraphPad Prism 7 (La Jolla, CA, USA).
Evaluation of CD13 Expression Levels in Selected
Cell Lines. Western blot studies were carried out to detect the
CD13 expression levels in HT-1080 and MCF-7 cells. The
cells (ATCC, Manassas, VA, USA) were lysed with cell lysis
buﬀer (Cell Signaling, Boston, MA, USA) and protein
concentrations were determined by the bicinchoninic acid
assay (BCA assay). Cell proteins (20 μg) were then loaded
into wells on sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE gel, Bio Rad, Hercules, CA,
USA). The proteins on gel was then transferred to the 0.45
μm nitrocellulose membrane (Bio Rad, Hercules, CA, USA),
blocked for 1 h with 5% w/v BSA in 0.1% Tween 20Trisbuﬀered saline and then incubated overnight at 4 °C with a
primary antibody (anti-CD13 antibody [EPR4058], Abcam,
Cambridge, MA, USA). The membrane was incubated with a
secondary antibody (donkey anti-rabbit IgG IRDye 800CW,
1:10 000) (LI-COR, Lincoln, NE, USA) in the blocking buﬀer
for 1 h at room temperature. The membrane was scanned
using a LI-COR Odyssey imaging system (Lincoln, NE, USA).
To normalize the protein loading, the blots were incubated
with β-actin (Cell Signaling, Boston, MA, USA) as a control.
Cell Surface CD13 Binding of the Peptides. For the cell
surface CD13 binding assay,50 CD13 positive HT-1080 cells

receptor strength of 5000. The glycan, solvent, and buﬀer
molecules as well as the endogenous ligand ANG IV were
removed from the docking simulation. Because the peptide
design approach is based on the KS protein packing and the
model does not take water-mediated intermolecular interactions in to account, the solvent molecules were removed
from the hCD13 crystal structure. Docking of the peptides was
performed on the hCD13’s peptide binding site using Dock
function with a rigid receptor protocol. As opposed to induced
ﬁt protocol which allows ﬂexible side chains, in the rigid
receptor protocol side chains of the receptor are held ﬁxed.
The rigid receptor protocol was used in the study as the
induced ﬁt protocol requires signiﬁcantly longer docking time
and higher computational power. Timeout (seconds) and no.
of return poses in the default triangle matcher placement
option of the docking window were conﬁgured to 500 and
2000, respectively. At the end of docking, MOE produced 100
possible conformations for each peptide and respective
docking score for the complex of peptides and hCD13.
Potential peptide candidates were selected using the docking
score from MOE. The docking score function estimates the
free energy of binding of the ligand from a given binding pose.
A low (negative) docking score indicates a stable system and
thus a likely interaction between the receptor and ligand.
Further docking studies were performed using a second
molecular modeling softwareAutoDock Vina.37 The hCD13
structure (PDB ID: 4FYS) was prepared using Dock Prep in
UCSF Chimera. The endogenous ligand ANG IV, glycans,
buﬀer, and water molecules were removed. The designed
peptide structures along with the positive control CNGRC
(C1−C5) peptide were generated in Chimera using Build
Structure function with default settings. The peptide structures
were then prepared using Dock Prep and Minimize Structure
functions. AutoDock Tools within MGLTools (version 1.5.6)
were used to generate the PDBQT format ﬁles of the peptides
and receptor. The docking was performed using the methods
described by Hauser and Windshügel38 and in AutoDock Vina
manual.39 The position of the grid box center was set at (x, y,
z) = (101.98, 20.068, 18.861), and the xyz dimensions of the
grid box were 80, 62, and 62 Å, respectively. The
exhaustiveness of the docking run was set at 100. A small set
of peptides was selected for further experimental evaluation
based on the AutoDock Vina predicted binding sites.
Peptide Synthesis and Characterization. The selected
designed peptides, CNGRC (C1−C5) peptide (NGR-2C),
and GARAG peptide (negative control), were synthesized by
the standard solid-phase synthesis method.40−44 The amino
acids and coupling reagents were obtained from Chem-Impex
(Wood Dale, IL, USA). Coupling of subsequent amino acids
was performed with 1-hydroxy-benzotriazole and diisopropylcarbodiimide. In case of the CNGRC (C1−C5) peptide, the
synthesis scheme started with Fmoc-L-Cys(Trt)-2-chlorotrityl
resin and cyclization was achieved by the formation of 1−5
disulﬁde bond using iodine in dimethylformamide (DMF) at 0
°C for 2 h.45 In case of ﬂuorescein isothiocyanate (FITC)
conjugated peptides, the synthesis was started with FmocLys(ivDde)-Wang resin (Peptides International, Louisville, KY,
USA) to maintain simple solid phase synthesis method and
easily place the probe toward C-terminal side.46 A linker (e.g.
6-aminohexanoic acid/Ahx) was added between the peptide
sequence and the lysine residue at the C-terminal. After
coupling the last Boc-protected amino acid at the N-terminal,
the resins were treated with 2% hydrazine to remove the ivDde
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ANG IV also forms ﬁve sockets, which pack knobs from
hCD13. For the 5-mer peptide design, six out of the nine
sockets and one additional free socket formed by residues
441Y, 442R, and 445A were selected as the target site surface
for the designed peptides (Figure 2C). For the designed
peptide ligand, positions 1, 2, and 5 were chosen as knobs to
pack into the binding sockets. At position 1, knobs were
chosen for 2 binding sites: one consisting of two sockets in the
helix and another consisting of a socket from a coil region.
Position 2’s knob only comes from the helix, whereas position
5’s knob is a single socket, but at 2 possible positions. Knobs
with high propensities to interact with these sockets were
chosen as the basis for the peptide sequences. Because these
sockets span between two types of secondary structure that are
12 Å apart at closest approach, two residues (positions 3 and 4
on the peptide) were necessary to bridge between the binding
sites.
All possible combinations of the highest propensity knobs
(Figure 2C inset table) produced 32 5-mer peptide sequences.
Using the predetermined criteria (previously discussed in the
Methods section), eight 5-mer peptides were selected from the
initial sequences and subjected to MOE docking. These eight
5-mer peptides were ranked according to their MOE docking
scores (Table 1). In case of 8-mer peptide design, a total of
384 peptides were obtained using all possible combinations of
the knobs (Figure 2D inset table) that subsequently led to 40
8-mer peptide sequences after applying the predetermined
criteria. These 40 peptides were subjected to MOE docking
and the top 10 ranking peptides (top 25% based on the MOE
docking score) are listed in Table 1.
Additional docking studies with AutoDock Vina were
performed for all eight of the 5-mer peptides and top 25%
(10) of the 8-mer peptides based on MOE docking score
ranking. Of these, AutoDock Vina predicted that three
designed peptides [two 5-mer (PEP20, GYPAY, and PEP24,
GFPAY), and one 8-mer (PEP173, GYPAVYLF)] could bind
to the intended active site of hCD13 similar to the positive
control CNGRC (C1−C5) peptide ligand (NGR-2C) (Figure
3 and Table 1). These three peptides along with two other
nonspeciﬁc peptides (PEP293, GYPAYVEF and PEP308,
GFPAVYEF; as negative controls) were selected for experimental evaluation.
Characterization of CD13 Binding Properties of the
Peptides. The enzyme inhibition assays were performed to
characterize the apparent aﬃnities of the peptides toward
CD13. The designed peptides inhibited the CD13 catalyzed
hydrolysis of Ala-MCA substrate, at signiﬁcantly lower
concentrations than NGR-2C peptide (Figure 4A and Table
2). The illustrated curve-ﬁttings are based on single inhibitor
binding site. IC50 values observed for the designed peptides
were 2.7−7.4 times lower than that of NGR-2C (Table 2). To
gain insights into the mode of inhibition of the peptide ligands,
steady-state enzyme kinetic assays (Figure 4B and Table 2)
were performed at room temperature. The Lineweaver−Burk
double reciprocal plots for PEP20, PEP24, PEP173, and NGR2C showed a series of lines crossing the y-axis (1/V0) at the
same pointthat is, Vmax unchanged, but with increasing
values of Michaelis constant (Km). These data were consistent
with competitive inhibition model (PEP20, Ki = 54.0 ± 11.9
μM; PEP24, Ki = 74.3 ± 12.0 μM; PEP173, Ki = 38.8 ± 5.21
μM; NGR-2C, Ki = 773 ± 157 μM), suggesting that PEP20,
PEP24, PEP173, and NGR-2C bind to the catalytic site of
CD13. On the other hand, PEP293 and PEP308 were found to

and CD13 negative MCF-7 cells were seeded at 3−4 × 104
cells/well, 48 h before the experiment in 96-well clear-bottom
black plates. On the day of experiment, the cells were washed
twice with binding buﬀer before incubating 30 min (37 °C, 5%
CO2) with each peptide conjugate (60 μM) in the binding
buﬀer. The cells were then ﬁxed with 4% paraformaldehyde in
PBS for 10 min. The ﬂuorescence intensities were measured
using the BioTek Synergy HT microplate reader with FITC
ﬁlter set. The cells were then counterstained with the nuclear
stain Hoechst 33342 and analyzed using the same microplate
reader with a DAPI ﬁlter set. Between each step, the cells were
washed twice with the binding buﬀer.
Confocal Microscopy. HT-1080 and MCF-7 cells were
seeded on to coverslips placed inside 6-well culture plates at a
density of 100 000 cells/well. The cells were allowed to attach
for 24 h before the experiment was performed. The cells were
incubated with FITC-conjugated peptides at a concentration of
30 μM at 37 °C, 5% CO2 for 20 min in binding buﬀer. Cells
were then stained with Alexa Fluor 594 (plasma membrane
dye) (Invitrogen), ﬁxed with 4% paraformaldehyde in PBS,
and visualized under a Leica DMIRE2 confocal laser scanning
microscope (Leica Microsystems GmbH, Germany) at 63×
magniﬁcation with oil immersion. Between each step, the cells
were washed twice with the binding buﬀer.

■

RESULTS
Peptide Design. Porcine CD13 (pCD12) and human
CD13 (hCD13) have high similarity of sequence (80% overall,
100% in the active site, 94% in the peptide-binding region).51
When the peptide-binding regions of hCD13 and pCD13 were
aligned and superposed using MOE, the overall root-meansquare deviation was 0.833 Å, indicative of signiﬁcant similarity
in their binding site conformation (Figure 1). The endogenous

Figure 1. Binding sites of hCD13 and pCD13 aligned and superposed
[blue structurehCD13, green coilANG IV, magenta structure
pCD13, yellow coilCNGRCG (C1−C5)].

ligand ANG IV and the peptide ligand CNGRCG (C1−C5)
were also observed to reside very close to each other (Figure
1). This suggested that the location where ANG IV binds on
hCD13 could be used as the target site for designing novel
peptide ligands.
Using the KS model,15−17 the complicated CD13 ligand
binding interface (Figure 2A) can be simpliﬁed and made more
intelligible by the two-dimensional map of quaternary packing
interactions shown in Figure 2B. A clear picture of the peptide
residue knobs from ANG IV packing into sockets on the
hCD13 surface is represented. There are nine sockets on
hCD13 ﬁlled by the knob residues coming from ANG IV.
5129
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Figure 2. (A) Binding site of hCD13 with the endogenous ligand ANG IV (magenta coil), (B) 2D lattice diagram of the binding interface between
hCD13 and ANG IV, (C) peptide design for the 5-mer, and (D) peptide design for the 8-mer. Sockets are represented by triangles or half-ellipses,
while residue knobs are shown as circles. Gray- and yellow-shaded sockets are the ﬁlled and empty sockets on hCD13, respectively. Blue-shaded
sockets are the hCD13 sockets used to select high propensity knobs for the peptide design. Knobs are colored based on their origin. Knobs involved
in tertiary structure packing within hCD13 are colored green from coil, red from helix, and blue from sheet. Knobs involved in quaternary binding
of the peptide ligand are colored magenta. Likewise, the knobs used in the peptide design are also colored magenta. Black circles represent the
knobs coming from the receptor which pack against sockets formed by endogenous/designed peptide ligand. In (C,D), receptor knobs were
omitted, and the inset table lists the high propensity knobs at each position.

Table 1. Designed Peptides with Docking Results
Residue→
Ranking

Peptide↓

1

2

3

4

5

6

7

8

MOE Docking Score

autoDock Vina predicted binding site

5-mer peptides
1
2
3
4
5
6
7
8

20
24
19
27
32
28
31
23
NGR-2C

G
G
G
G
G
G
G
G
C

Y
F
Y
I
L
I
L
F
N

P
P
P
P
P
P
P
P
G

A
A
A
A
A
A
A
A
R

Y
Y
V
V
Y
Y
V
V
C(1−5)

1
2
3
4
5
6
7
8
9
10

296
293
317
389
209
161
308
173
387
245

G
G
G
G
G
G
G
G
G
G

Y
Y
I
L
F
Y
F
Y
L
I

P
P
P
P
P
P
P
P
P
P

A
A
A
A
A
A
A
A
A
A

V
Y
Y
Y
V
Y
V
V
Y
V

8-mer peptides
Y
E
F
V
E
F
V
E
F
V
Y
F
Y
L
F
V
Y
F
Y
E
F
Y
L
F
V
Y
L
Y
L
F

5130

−13.9095
−11.9234
−11.7211
−11.6586
−11.5135
−11.3576
−10.7643
−10.7205
−11.2815

on active site
on active site
distant from active
distant from active
distant from active
distant from active
distant from active
distant from active
on active site

−16.9475
−16.6503
−16.6490
−16.5394
−16.4622
−16.3548
−16.2962
−16.2385
−16.0129
−15.8007

distant from active
distant from active
distant from active
distant from active
distant from active
distant from active
distant from active
on active site
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lower the Vmax, without aﬀecting Km (Figure 4B), suggesting
that they can bind to CD13 in the presence of a substrate. This
indicates noncompetitive inhibition mode of PEP293 and
PEP308. The values of the kinetic parameters (global Vmax and
Km) are listed in Table S3. The similarity between the
experimental and simulated binding characteristics of the
peptides is explained later (see discussion, Tables 1 and 2, and
Figures 3 and 4).
CD13 Expression Levels in Selected Cell Lines. In the
western blot studies, while HT-1080 cells exhibited clear CD13
bands, MCF-7 cells did not show signiﬁcantly identiﬁable band
of CD13 in the blots (Figure 5A). On the basis of the band

Figure 3. Peptides (coil structures) at hCD13 binding site after
docking with AutoDock Vina. Green: NGR-2C, blue: PEP20, yellow:
PEP24, magenta: PEP173, wheat: PEP293, gray: PEP308.

Figure 4. Eﬀect of diﬀerent peptides on CD13 enzymatic activity. (A) CD13 catalysis inhibition by the peptides (n = 3, mean ± SE in duplicate or
triplicate). (B) Steady-state kinetic analysis of CD13 in the presence of the Ala-MCA substrate and diﬀerent peptide inhibitors; plots of initial
velocity (V0) vs Ala-MCA concentration (upper panels) and double reciprocal plots (lower panels) (mean ± SE, in triplicate).
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Table 2. CD13 Catalysis Inhibition Assay Data
peptides

sequence

PEP20
PEP24
PEP173
NGR-2C (+ve control)
GARAG (-ve control)
PEP293
PEP308

GYPAY
GFPAY
GYPAVYLF
CNGRC (C1−C5)
GARAG
GYPAYVEF
GFPAVYEF

IC50 (μM)a,b
227
463
170
1260

±
±
±
±

binding aﬃnity, Ki (μM)c,d

6.67
21.8
23.0
80.0

213 ± 6.67
300 ± 40.0

54.0
74.3
38.8
773

±
±
±
±

11.9
12.0
5.21
157

137 ± 8.31
234 ± 14.3

inhibition mode as determined from double reciprocal plots
competitive
competitive
competitive
competitive
noncompetitive
noncompetitive

a
n = 3, mean ± SE. bAll after 30 min except NGR-2C after 10 min. cMean ± SE. dCompetitive inhibition model was used in Prism 7 to determine
the Ki for PEP20, 24, 173, and NGR-2C, whereas noncompetitive inhibition model was used for PEP293 and 308.

Figure 5. (A) CD13 expression levels in HT-1080 and MCF-7 cells (mean ± SE, in triplicate) (B) binding of the peptide conjugates to HT-1080
and MCF-7 cells (mean ± SE, in quadruplicate).

Figure 6. Evaluation of selectivity of the peptide conjugates. GreenFITC conjugated peptides, redAlex Fluor plasma membrane dye.

intensity, HT-1080 cells showed 10-fold greater CD13
expression than MCF-7 cells. These data showed the suitability
of using HT-1080 and MCF-7 cells as the CD13 positive and
negative cell lines, respectively.
Cell Surface CD13 Binding of the Peptides. The ability
of the peptides to recognize the cell surface CD13 receptor was
evaluated by measuring the ﬂuorescence intensity (cell number
normalized) after incubating the FITC-conjugated peptides in
CD13 positive HT-1080 cells and CD13 negative MCF-7 cells.
In the cell binding assay, all the FITC conjugated peptides
except the negative control conjugate (GARAG-FITC),
showed signiﬁcantly higher cell surface binding to CD13
positive HT-1080 cells as compared to the CD13 negative
MCF-7 cells (Figure 5B). Additionally, the designed peptide
(PEP20, PEP24, and PEP173) conjugates were found to
exhibit slightly higher cell surface binding compared with
NGR-2C conjugate in HT-1080 cells. These data suggested

that the designed peptides could recognize and bind to the
CD13 receptors on the cell surface.
Characterization of the Cell Internalization and
Selectivity of the Peptides toward CD13. Cell internalization and selectivity of the designed peptides toward CD13
were evaluated in HT-1080 and MCF-7 cell lines using
confocal microscopy.52,53 Confocal microscopy imaging was
performed after incubating the cells with the FITC-conjugated
peptides for 20 min. In the HT-1080 cell images (Figure 6
upper panel), signiﬁcant ﬂuorescence was observed inside the
cells and some ﬂuorescence was detected on the cell surface for
the designed peptides (PEP20-FITC, PEP24-FITC, and
PEP173-FITC) and NGR-2C-FITC. The same molecules
resulted in only background ﬂuorescence in MCF-7 cell images
(Figure 6 lower panel). FITC-labeled control peptide GARAG
showed no binding to both the cell lines. These data
demonstrated that the designed FITC-labeled peptides and
the positive control NGR-2C-FITC bound and got internal5132
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Figure 7. Ligand−receptor interaction diagrams. (A) Interaction of docked PEP20 at lowest energy conformation, (B) interaction of docked
PEP173 at lowest energy conformation, and (C) interaction of docked NGR-2C at lowest energy conformation.

In this study, a KS analysis of the protein-packing structure
was used to rationally design peptide ligands with speciﬁcity
for the CD13 active site. The method begins with mapping the
target protein-binding site to characterize the amino acid
packing arrangements in terms of three residue sockets on the
target receptor that pack ligand knob residuesin this study
the prototype receptor used was CD13. From the sockets
identiﬁed as important for ligand binding on the surface of
CD13, a set of knobs with high propensity interactions were
selected. This set of amino acids enabled peptide sequences to
be designed rationally by predicting the packing of the peptide
ligand at the binding site. The peptides were screened in silico
by docking programs to identify the best peptide candidates.
From the design approach, 412 potential peptide sequences
were reduced to just 3 candidates. The three identiﬁed
peptides showed selective binding to human CD13 receptor in
vitro. In the enzymatic assay, the designed peptides exhibited
higher CD13 catalysis inhibition than the CNGRC (C1−C5)
peptide (NGR-2C). NGR-2C showed signiﬁcantly reduced
inhibition of CD13 enzymatic activity within 30 min (Figure
4A), suggestive of its unstable physicochemical characteristics
at the assay condition. This phenomenon is not unexpected
because the NGR-2C peptide has been reported to lose the
CD13 binding ability rapidly through deamidation of the Asn
residue.58 The success of therapeutic peptides or peptide
ligands depends on the delivery of their active form at the
target site. The physicochemical stability of the peptides is
largely inﬂuenced by the amino acid composition and
sequences of the peptides.59−61 In our rational design method,

ized in the CD13 positive HT-1080 cells but not CD13
negative MCF-7 cells.

■

DISCUSSION
The structure-based design plays a crucial role in developing
novel molecules/drugs. This approach to ligand design utilizes
three-dimensional information of a target protein to improve
recognition and discrimination by identifying favorable residue
interactions. The ﬁrst therapeutic peptide designed from
crystal structure analysis was enfuvirtide, which received the
US-FDA approval as an anti-HIV peptide in 2003.54 Foy et
al.55 designed vaccines against EGFR by selecting diﬀerent
regions from the crystal structure of the protein. A VEGFR-3
targeted peptide ligand was developed by analyzing the crystal
structure of the extracellular domain of VEGFR-3.56 Recently,
Joshi et al.57 reported the design of a peptide that inhibits the
enzymatic activity of CD13. The peptide was developed by a
substrate-based approach where crystal structures of CD13
with diﬀerent amino acids were solved to determine the
structural basis of the substrate speciﬁcity. The structural
insights into the protein−ligand interaction obtained from the
crystal structures have culminated in a number of computational peptide design approaches. However, it is quite evident
that the majority of these approaches are based on either
sequence motifs or protein complexes.8 A rational design
method based on the predicted interaction between target and
ligand molecule will signiﬁcantly speed up this development
process.
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peptides having potentially unstable amino acids or sequences
can be excluded at the very beginning of the development
works during peptide screening phase.
The three identiﬁed peptides [PEP173 (GYPAVYLF),
PEP20 (GYPAY) and PEP24 (GFPAY)] showed 10−20
times higher binding aﬃnity (Ki) toward hCD13 as compared
to NGR-2C peptide (773 μM) (Table 2). In other reported
studies, IC50 of the NGR-2C peptide was 300−515 μM, and
the Ki was 134 μM.49,50 Unlike the ﬂuorescence-based method
used in the present study, those reported experiments used
either L-leucine-p-nitroanilide or L-alanine-p-nitroanilide as the
catalysis substrate, and the formation of p-nitroaniline product
was measured by the absorbance at 405 nm. The compositions
of the assay buﬀer were also diﬀerent in these studies. But
generally, ﬂuorescence-based detection techniques are more
sensitive than the absorbance-based methods.62
The MOE ligand−receptor interaction analysis indicated
that the higher binding aﬃnity of the designed peptides as
compared to the positive control NGR-2C peptide is possibly
due to higher number of interactions with the receptor protein.
While the number of interactions for the docked PEP20, 24,
and 173 were 8, 7, and 10, respectively, the docked NGR-2C
peptide was seen to make ﬁve interactions with the hCD13
protein structure. The ligand−receptor interaction diagrams of
PEP20, 173, and NGR-2C are presented in Figure 7. Ranking
of the three peptides (PEP173, PEP20, and PEP24,
respectively) according to their experimental binding aﬃnities,
Ki, (38.8, 54.0, 74.3 μM, respectively) was found to be in
agreement with the ranking predicted by the MOE docking
scores (−16.2385, −13.9095, −11.9234 kcal/mol, respectively) and number of interactions (10, 8, and 7, respectively).
Additionally, as predicted by the AutoDock Vina (Figure 3 and
Table 1), PEP20, 24, and 173 were found to bind to the
catalytic active site of CD13 in the experimental steady-state
enzyme kinetic assay (Figure 4B and Table 2). AutoDock Vina
also accurately predicted the distant binding sites of the
nonspeciﬁc control peptides [PEP293 (GYPAYVEF) and
PEP308 (GFPAVYEF)] as experimentally conﬁrmed by their
observed noncompetitive inhibition mode in enzymatic assay
(Figure 4B and Table 2). These ﬁndings suggest that the
combination of multiple docking platforms in our design
method could accurately predict the binding characteristics
(aﬃnity ranking and binding site) of the designed peptide
ligands. Data from the cell binding and confocal microscopy
assays (Figures 5 & 6) further demonstrated that the designed
peptides could recognize and selectively bind to the CD13 on
the cell membrane.
The NGR-motif containing peptide ligand (i.e., CNGRC)
for CD13 was ﬁrst identiﬁed by an in vivo phage display
selection study in a mouse model.20,21 Thus, the prototype
target, CD13 receptor, allowed us to compare the performance
of our rational peptide ligand design method with the
structure-free design technique in terms of in vitro binding
aﬃnity and selectivity of the identiﬁed peptide ligands. A
typical in vivo phage display screening starts with generating a
large library of phage particles expressing a wide array of
peptides on their surface. The size of the library can reach up
to 108 to 109 diﬀerent variants.63 The phage display library
proceeds through a number of enrichment screening cycles,
which involves binding, phage ampliﬁcation, and plaque
isolation. The ﬁnal step is sequencing. Additional validation
of the interaction may involve immunohistochemistry, real
time PCR, bio-distribution, and homing inhibition studies.64

On the other hand, our design method rationally identiﬁed
CD13 selective peptide ligands having better in vitro binding
aﬃnity with much less screening and experimental complexity.

■

CONCLUSIONS
In the present study, a rational peptide ligand design method
based on the KS model of protein packing was developed and
successfully employed to identify three novel peptide ligands
for the model receptor, CD13. The identiﬁed peptides showed
good selectivity and higher binding aﬃnity toward the hCD13
receptor in vitro as compared to the known peptide ligand
CNGRC (C1−C5). Our study demonstrated the feasibility of
the rational method to design novel peptide ligands. Most
importantly, the rational method excluded the need of long
experimental screening of a vast library of peptide sequences,
and thus signiﬁcantly reduces the time and resources
traditionally employed to identify such molecules.
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